Pepgen announces first patient dosed in phase 1 freedom-dm1 clinical trial of pgn-edodm1 for myotonic dystrophy type 1 (dm1)

- safety, transcript splicing correction and clinical outcome measures data at 5 mg/kg pgn-edodm1 dose level in patients from freedom-dm1 clinical trial expected in 2024 -

PEPG Ratings Summary

PEPG Quant Ranking